3.Fujino T et al. Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. https://www.ncbi.nlm.nih.gov/pubmed/31279006 4.Kim S et al . Acquired Resistance of...
近日,迈杰转化医学宣布其自主研发的两款产品获CE认证,分别为人微卫星不稳定性(MSI)检测试剂盒(荧光PCR-毛细管电泳法),Human Microsatellite Instability (MSI) Detection Kit (Fluorescence PCR-Capillary Electrophoresis)和人c-MET外显子14跳读突变检测试剂盒(荧光PCR法),Human c-MET Exon 14 Skipping Mutation Dete...
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. Clin Cancer Res. 2020 Jun 1;26(11):2615-2625. doi: 10.1158/1078-0432.CCR-19-3608. Epub 2020 Feb 7. PMID: 32034073. ⑽OA15.04 - Telisotuzumab Vedotin (teliso-v) ...
另外克唑替尼对MET与7号染色体着丝粒的比率为4以上,1.8-2.2之间患者的疗效分别为38.1%、14.3%,这也可能表明除了c-Met 14号外显子跳跃突变以外,这些药物对c-Met扩增或者高表达的患者也具有一定的疗效,只是其疗效没有c-Met 14号外显子跳跃突变那么显著,而对低表达或...
Vebreltinib for Advanced Non–Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study Article 作者:Wang, Zhe-Hai;Yao, Yu;Hu, Jie;Cheng, Ying;Zhang, Wei;Yang, Jin-Ji;Chen, Yuan;Shi, He-Peng;Xue, Wei-Zhe;Wu, Lin;Chen, Ji...
Cohort 1 included patients with MET exon 14 skipping (METex14)鈥搈utant NSCLC who had not previously received MET inhibitors. Participants were administered vebreltinib at a dosage of 200 mg twice a day in 28-day cycles. The primary end point was the objective response rate (ORR), and ...
NGS结果:KRAS,EGFR,BRAF未发现驱动变异。ALK,ROS1未发现融合。 MET 14号外显子发现c.3028G>A (AF,94%; DP,867) 高水平的MET扩增。 qRT-PCR结果:Exon 14 skipping。 治疗方案:250mg crizotinib ,每天两次,8 周疗程。 治疗结果:肿瘤明显变小
1.Shun Lu, et al. A Phase 3b Study of Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation. 2024 ELCC. Abs 1MO. 2.中国老年保健协会肺癌专业委员会. 《非小细胞肺癌MET临床检测中国专家共识》.Zhongguo Fei Ai Za Zhi. 2023 Jun 20; 26(6): 416–...
c-MET通路异常激活主要原因是MET 14号外显子跳跃突变等。外显子最后一个核苷酸的点突变经常导致外显子跳读(exon skipping)。正常情况下，MET 14号外显子侧翼的内含子可在前mRNA中被剪接出来，含MET 14号外显子的mRNA可以被正常翻译成为功能性MET受体。 当MET 14号外显子发生特定点突变，可能导致MET基因转录...
some selective tyrosine kinase inhibitors (TKIs) of MET has been approved for non-small cell lung cancer with MET gene 14 exon skipping mutation, such as Glumetinib, Savolitinib, Tepotinib, Capmatinib, etc. Drugs that target secondary MET amplification are still in clinical trials. This paper...